-
Mashup Score: 0Epcoritamab receives approval from EC and Japan Ministry of Health, Labour and Welfare for R/R LBCL - 8 month(s) ago
Epcoritimab has received approval from the European Commission and Ministry of Health, Labour and Welfare of Japan for patients with R/R LBCL after positive results from EPCORE NHL-1 and NHL-3 clinical trials.
Source: lymphomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Thea Pharma launches Iyuzeh in US - 8 month(s) ago
Thea Pharma has launched Iyuzeh in the U.S. for the treatment of primary open-angle glaucoma or ocular hypertension.
Source: www.healio.comCategories: Latest Headlines, OphthalmologyTweet
-
Mashup Score: 0Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943 | Vincerx Pharma - 8 month(s) ago
Phase 1 trial enrolling patients with relapsed/refractory AML, MDS and B-cell ALL PALO ALTO, Calif. , Sept. 14, 2023 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through
Source: investors.vincerx.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Vididencel received fast track designation from the U.S. FDA - 8 month(s) ago
On September 8, 2023, vididencel, an off-the-shelf, intradermal vaccine, received fast track designation from the FDA for the treatment of patients with AML in CR with residual disease.
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Bexmarilimab granted orphan drug designation by the U.S. FDA - 9 month(s) ago
On August 29, 2023, the U.S. FDA granted orphan drug designation to bexmarilimab, a first-in-class humanized monoclonal antibody, for the treatment of patients with AML.
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2New NCCN guidelines for pediatric patients with Hodgkin lymphoma and their families - 9 month(s) ago
The NCCN has published guidelines for patients with Hodgkin lymphoma and their families, providing a clear review of every aspect of the disease.
Source: lymphomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]
Source: www.nice.org.ukCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2
Phase 1 trial expected to begin in early Q4 2023 VIP943 is Vincerx’ first candidate from next-generation ADC platform and its second IND clearance within 8 months, highlighting Vincerx’s development and regulatory expertise PALO ALTO, Calif. , Aug. 22, 2023 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc.
Source: investors.vincerx.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML - 9 month(s) ago
Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML
Source: www.gilead.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2BITT Announces FDA Acceptance of IND for TNFR2 Antibody - 9 month(s) ago
The FDA has cleared BITT’s IND application for a Phase I trial of BITT2101 (anti-TNFR2) in patients with relapsed/refractory Non-Hodgkin’s lymphomas
Source: www.businesswire.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🚨 NEWS 🚨 @US_FDA has cleared an Investigational New Drug application for a phase I trial of anti-TNFR2 in patients with R/R NHL. Elevated levels of soluble TNFR2 were reported in patients with NHL; TNFR2 is linked to disease progression. https://t.co/KQx3q8nhiS #lymsm #mednews https://t.co/VNKiyh0da7
-
🚨 NEWS 🚨 @EU_Commission and Ministry of Health, Labour and Welfare of Japan approved epcoritamab for patients with R/R LBCL. Read more here 👉 https://t.co/EDVfhwsVHy #lymsm #mednews https://t.co/WEfAzD6kqx